Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**1-Aminocyclopropanecarboxylic acid (ACPC)** is a non-proteinogenic alpha-amino acid consisting of a cyclopropane ring with amino and carboxyl substituents at the same position. It is best known as an intermediate in the biosynthesis of ethylene in plants and acts as a plant metabolite and ethylene releaser[1][8]. In mammals, ACPC functions as a partial agonist at the strychnine-insensitive glycine recognition site on the N-methyl-D-aspartate (NMDA) receptor complex. This action modulates NMDA receptor activity—enhancing or inhibiting function depending on ambient glutamate and glycine concentrations[3][4]. Preclinical studies show that ACPC has neuroprotective effects (reducing seizure induction and cell death after NMDA exposure), procognitive effects (improving object recognition memory and cognitive flexibility), anticonvulsant properties, anxiolytic-like actions, anti-addictive potential by preventing opioid tolerance development when co-administered with opioids in animal models[3][8][9]. It does not significantly affect attention or impulsivity but may have antipsychotic-like effects via modulation of NMDA receptor function[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-aminocyclopropanecarboxylic acid.